Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors

被引：0

作者：

Della-Morte, David ^{[1
,2
,3
]}

Palmirotta, Raffaele ^{[3
]}

Rehni, Ashish K. ^{[2
]}

Pastore, Donatella ^{[1
]}

Capuani, Barbara ^{[1
]}

Pacifici, Francesca ^{[1
]}

De Marchis, Maria Laura ^{[3
]}

Dave, Kunjan R. ^{[2
]}

Bellia, Alfonso ^{[1
]}

Fogliame, Giuseppe ^{[4
]}

Ferroni, Patrizia ^{[3
]}

Donadel, Giulia ^{[1
]}

Cacciatore, Francesco ^{[5
]}

Abete, Pasquale ^{[6
]}

Dong, Chuanhui ^{[2
]}

Pileggi, Antonello ^{[7
]}

Roselli, Mario ^{[1
]}

Ricordi, Camillo ^{[7
]}

Sbraccia, Paolo ^{[1
,4
]}

Guadagni, Fiorella ^{[3
]}

Rundek, Tatjana ^{[2
]}

lauro, Davide ^{[1
,4
]}

机构：

[1] Univ Roma Tor Vergata, Sch Med, Dept Syst Med, I-00133 Rome, Italy

[2] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA

[3] IRCCS San Raffaele Pisana, Interinst Multidisciplinary Biobank BioBIM, Biomarker Discovery & Adv Technol BioDAT, Rome, Italy

[4] Tor Vergata Fdn Hosp, Div Internal Med, Rome, Italy

[5] IRCCS Salvatore Maugeri, Telese Terme, BN, Italy

[6] Univ Naples Federico II, Dept Clin Med Cardiovasc Sci & Immunol, Cattedra Geriatria, Naples, Italy

[7] Univ Miami, Diabet Res Inst, Miller Sch Med, Miami, FL 33136 USA

来源：

PHARMACOGENOMICS | 2014年 / 15卷 / 16期

关键词：

cardiovascular disease; diabetes; pharmacogenetics; pharmacogenomics; single nucleotide polymorphisms; thiazolidinediones; vascular risk factors; ACTIVATED-RECEPTOR-GAMMA; ISCHEMIA-REPERFUSION INJURY; ADIPONECTIN GENE POLYMORPHISM; ORAL ANTIDIABETIC DRUGS; OBESITY-RELATED TRAITS; PPAR-GAMMA; INSULIN-RESISTANCE; CHINESE PATIENTS; ADIPOSE-TISSUE; ROSIGLITAZONE RESPONSE;

D O I：

10.2217/PGS.14.162

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The most important goal in the treatment of patients with diabetes is to prevent the risk of cardiovascular disease (CVD), the first cause of mortality in these subjects. Thiazolidinediones (TZDs), a class of antidiabetic drugs, act as insulin sensitizers increasing insulin-dependent glucose disposal and reducing hepatic glucose output. TZDs including pioglitazone, rosiglitazone and troglitazone, by activating PPAR-gamma have shown pleiotropic effects in reducing vascular risk factors and atherosclerosis. However, troglitazone was removed from the market due to its hepatoxicity, and rosiglitazone and pioglitazone both have particular warnings due to being associated with heart diseases. Specific genetic variations in genes involved in the pathways regulated by TDZs have demonstrated to modify the variability in treatment with these drugs, especially in their side effects. Therefore, pharmacogenomics and pharmacogenetics are an important tool in further understand intersubject variability per se but also to assess the therapeutic potential of such variability in drug individualization and therapeutic optimization.

引用

页码：2063 / 2082

页数：20

共 122 条

[31] Metabolic activation of troglitazone: Identification of a reactive metabolite and mechanisms involved [J].

He, K ;

Talaat, RE ;

Pool, WF ;

Reily, MD ;

Reed, JE ;

Bridges, AJ ;

Woolf, TF .

DRUG METABOLISM AND DISPOSITION, 2004, 32 (06) :639-646

[32] Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders [J].

Honda, Tsuyoshi ;

Kaikita, Koichi ;

Tsujita, Kenichi ;

Hayasaki, Takanori ;

Matsukawa, Masakazu ;

Fuchigami, Shunichiro ;

Sugiyama, Seigo ;

Sakashita, Naomi ;

Ogawa, Hisao ;

Takeya, Motohiro .

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2008, 44 (05) :915-926

[33] Common polymorphisms of the peroxisome proliferator-activated receptor-γ (Pro12Ala) and peroxisome prolderator-activated receptor-γ coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus [J].

Hsieh, Ming-Chia ;

Lin, Kun-Der ;

Tien, Kai-Jen ;

Tu, Shih-Te ;

Hsiao, Jeng-Yueh ;

Chang, Shun-Jen ;

Lin, Shiu-Ru ;

Shing, Shih-Jang ;

Chen, Hung-Chun .

METABOLISM-CLINICAL AND EXPERIMENTAL, 2010, 59 (08) :1139-1144

[34] Drug-Induced Idiosyncratic Hepatotoxicity: Prevention Strategy Developed after the Troglitazone Case [J].

Ikeda, Toshihiko .

DRUG METABOLISM AND PHARMACOKINETICS, 2011, 26 (01) :60-70

[35] Suppression of rat thromboxane synthase gene transcription by peroxisome proliferator-activated receptor γ in macrophages via an interaction with NRF2 [J].

Ikeda, Y ;

Sugawara, A ;

Taniyama, Y ;

Uruno, A ;

Igarashi, K ;

Arima, S ;

Ito, S ;

Takeuchi, K .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (42) :33142-33150

[36] Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates myocardial ischernia/reperfusion injury in a rat model [J].

Ito, H ;

Nakano, A ;

Kinoshita, M ;

Matsumori, A .

LABORATORY INVESTIGATION, 2003, 83 (12) :1715-1721

[37]

Jazet IM, 2003, NETH J MED, V61, P194

[38] Pioglitazone decreased CD40/CD40L expression on human umbilical vein endothelial cells induced by oxidized low-density lipoprotein [J].

Jiang, De-qian ;

Chu, Luo-xiang ;

Liu, Zhao-yun ;

Zhang, Shun-bao .

CLINICA CHIMICA ACTA, 2006, 370 (1-2) :94-99

[39] Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARγ agonists [J].

Jiang, GQ ;

Dallas-Yang, Q ;

Li, ZH ;

Szalkowski, D ;

Liu, FL ;

Shen, XL ;

Wu, M ;

Zhou, GC ;

Doebber, T ;

Berger, J ;

Moller, DE ;

Zhang, BB .

DIABETES, 2002, 51 (08) :2412-2419

[40] Effect of Cytochrome P450 2C8*3 on the Population Pharmacokinetics of Pioglitazone in Healthy Caucasian Volunteers [J].

Kadam, Rajendra ;

Bourne, David ;

Kompella, Uday ;

Aquilante, Christina .

BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2013, 36 (02) :245-251

← 1 2 3 4 5 6 7 8 9 10 →